SG11202000444PA - Sequencing output determination and analysis with target-associated molecules in quantification associated with biological targets - Google Patents

Sequencing output determination and analysis with target-associated molecules in quantification associated with biological targets

Info

Publication number
SG11202000444PA
SG11202000444PA SG11202000444PA SG11202000444PA SG11202000444PA SG 11202000444P A SG11202000444P A SG 11202000444PA SG 11202000444P A SG11202000444P A SG 11202000444PA SG 11202000444P A SG11202000444P A SG 11202000444PA SG 11202000444P A SG11202000444P A SG 11202000444PA
Authority
SG
Singapore
Prior art keywords
target
spike
international
associated molecules
molecules
Prior art date
Application number
SG11202000444PA
Inventor
David Tsao
Oguzhan Atay
Original Assignee
Billiontoone Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Billiontoone Inc filed Critical Billiontoone Inc
Publication of SG11202000444PA publication Critical patent/SG11202000444PA/en

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2535/00—Reactions characterised by the assay type for determining the identity of a nucleotide base or a sequence of oligonucleotides
    • C12Q2535/101—Sanger sequencing method, i.e. oligonucleotide sequencing using primer elongation and dideoxynucleotides as chain terminators

Abstract

performingone or more sequencing operations, such as based on the one or more spike-in mixtures S determining one or more abundance metrics, such as based on the one or more sequencing operations for the one or more spike-in mixtures S140 facilitating characterization of one or more conditions (e.g., based on the one or more abundance metrics) S150 r (12) INTERNATIONAL APPLICATION PUBLISHED (19) World Intellectual Property Organization International Bureau UNDER THE PATENT COOPERATION TREATY (PCT) vitivio VIII oviolo v1111 tomo vimiE (10) International Publication Number WO 2019/028470 A2 (43) International Publication Date 07 February 2019 (07.02.2019) WIP0 I PCT (72) Inventors: TSAO, David; 2627 Hanover Street, Palo Alto, CA 94304 (US). ATAY, Oguzhan; 2627 Hanover Street, Palo Alto, CA 94304 (US). (74) Agent: SCHOX, Jeffrey; 500 3rd Street, Suite 215, San Francisco, CA 94107 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (51) International Patent Classification: C12Q 1/6869 (2018.01) (21) International Application Number: PCT/US2018/045419 (22) International Filing Date: 06 August 2018 (06.08.2018) English English (25) Filing Language: (26) Publication Language: (30) Priority Data: 62/541,565 04 August 2017 (04.08.2017) US (71) Applicant: BILLIONTOONE, INC. [US/US]; 2627 Hanover Street, Palo Alto, CA 94304 (US). (54) Title: SEQUENCING OUTPUT DETERMINATION AND ANALYSIS WITH TARGET-ASSOCIATED MOLECULES IN QUANTIFICATION ASSOCIATED WITH BIOLOGICAL TARGETS r validating one or more sample processing and/or computational processing approaches S105 processing a set of reference- associated molecules S115 generating a set of target-associated molecules associated with one or more biological targets S110 generating at least one spike-in mixture (e.g., based on the set of target-associated molecules, the set of reference-associated molecules, and one or more biological samples) S120 repeat with additional biological sample(s); for any suitable conditions facilitating treatment for the one or more conditions (e.g., based on the one or more abundance metrics) S160 FIGURE 1A (57) : Embodiments of a method and/or system can include generating a set of target- associated molecules (e.g., spike-in molecules) associated with one or more biological targets; generating one or more spike-in mixtures based on processing the set of target- associated molecules with one or more samples including the one or more biological targets; performing one or more Sanger sequencing operations on the one or more spike- in mixtures; determining one or more abundance metrics based on chromatogram- related outputs from the one or more Sanger sequencing operations; and/or facilitating characterization of one or more medical conditions based on the one or more abundance metrics. C N 00 C 1-1 C [Continued on next page] WO 2019/028470 A2 MIDEDIMOHIMIRDEIHNIMUMEHMEDIMIE (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: without international search report and to be republished upon receipt of that report (Rule 48.2(g))
SG11202000444PA 2017-08-04 2018-08-06 Sequencing output determination and analysis with target-associated molecules in quantification associated with biological targets SG11202000444PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762541565P 2017-08-04 2017-08-04
PCT/US2018/045419 WO2019028470A2 (en) 2017-08-04 2018-08-06 Sequencing output determination and analysis with target-associated molecules in quantification associated with biological targets

Publications (1)

Publication Number Publication Date
SG11202000444PA true SG11202000444PA (en) 2020-02-27

Family

ID=65234231

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202000444PA SG11202000444PA (en) 2017-08-04 2018-08-06 Sequencing output determination and analysis with target-associated molecules in quantification associated with biological targets

Country Status (12)

Country Link
US (2) US11430543B2 (en)
EP (1) EP3662085B1 (en)
JP (2) JP6955732B2 (en)
KR (1) KR102372572B1 (en)
CN (1) CN111094583A (en)
AU (1) AU2018312117B2 (en)
BR (1) BR112020002260A2 (en)
CA (2) CA3202766A1 (en)
ES (1) ES2923478T3 (en)
IL (1) IL272399A (en)
SG (1) SG11202000444PA (en)
WO (1) WO2019028470A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11646100B2 (en) 2017-08-04 2023-05-09 Billiontoone, Inc. Target-associated molecules for characterization associated with biological targets
US11519024B2 (en) 2017-08-04 2022-12-06 Billiontoone, Inc. Homologous genomic regions for characterization associated with biological targets
WO2020174406A1 (en) * 2019-02-28 2020-09-03 Inivata Ltd. Method for quantifying the amount of a target sequence in a nucleic acid sample
US20210057038A1 (en) * 2019-07-25 2021-02-25 Prime Discoveries, Inc. Systems and methods for microbiome based sample classification
WO2021142769A1 (en) * 2020-01-17 2021-07-22 深圳华大智造科技有限公司 Method for synchronously sequencing sense strand and antisense strand of dna
US11769332B2 (en) * 2020-06-15 2023-09-26 Lytx, Inc. Sensor fusion for collision detection
EP4314336A1 (en) * 2021-03-23 2024-02-07 BillionToOne, Inc. Fragment analysis for quantitative diagnostics of biological targets

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7655443B1 (en) 1999-05-07 2010-02-02 Siemens Healthcare Diagnostics, Inc. Nucleic acid sequencing with simultaneous quantitation
US7709194B2 (en) 2004-06-04 2010-05-04 The Chinese University Of Hong Kong Marker for prenatal diagnosis and monitoring
KR100808312B1 (en) * 2004-07-26 2008-02-27 홍경만 Method for measuring the chromosome, gene or nucleotide sequence copy numbers using co-amplification of artificial SNP sequences
US20070009884A1 (en) 2005-04-11 2007-01-11 Ghc Technologies, Inc. Methods and apparatuses for detecting chemical or biological agents
GB2425337A (en) 2005-04-22 2006-10-25 Uponor Innovation Ab Electrofusion fitting to seal barrier layer of composite pipe
US10081839B2 (en) 2005-07-29 2018-09-25 Natera, Inc System and method for cleaning noisy genetic data and determining chromosome copy number
US20070092869A1 (en) 2005-10-24 2007-04-26 Fulmer-Smentek Stephanie B Spike-in controls and methods for using the same
BRPI0713294B1 (en) 2006-06-29 2019-04-02 Shell Internationale Research Maatschappij B.V. METHOD AND CYCLONIC LIQUID GASIFICATION SEPARATOR TO DEGASTE A FLUID MIXTURE
US20080124712A1 (en) 2006-10-26 2008-05-29 Hantash Feras M Alpha globin gene dosage assay
HUE031849T2 (en) 2008-09-20 2017-08-28 Univ Leland Stanford Junior Noninvasive diagnosis of fetal aneuploidy by sequencing
TWI350312B (en) 2009-03-16 2011-10-11 Univ Kaohsiung Medical Method for determining smn gene transfer and intragenic mutations
PT3241914T (en) 2009-11-05 2019-04-30 Sequenom Inc Fetal genomic analysis from a maternal biological sample
DK2516680T3 (en) 2009-12-22 2016-05-02 Sequenom Inc Method and kits to identify aneuploidy
WO2011085491A1 (en) 2010-01-15 2011-07-21 The University Of British Columbia Multiplex amplification for the detection of nucleic acid variations
WO2011090556A1 (en) 2010-01-19 2011-07-28 Verinata Health, Inc. Methods for determining fraction of fetal nucleic acid in maternal samples
EP2366031B1 (en) 2010-01-19 2015-01-21 Verinata Health, Inc Sequencing methods in prenatal diagnoses
US10662474B2 (en) 2010-01-19 2020-05-26 Verinata Health, Inc. Identification of polymorphic sequences in mixtures of genomic DNA by whole genome sequencing
US20120270739A1 (en) 2010-01-19 2012-10-25 Verinata Health, Inc. Method for sample analysis of aneuploidies in maternal samples
US20130261196A1 (en) 2010-06-11 2013-10-03 Lisa Diamond Nucleic Acids For Multiplex Organism Detection and Methods Of Use And Making The Same
AU2011280996B2 (en) * 2010-07-23 2017-03-30 President And Fellows Of Harvard College Methods for detecting signatures of disease or conditions in bodily fluids
EP2596127A2 (en) 2010-07-23 2013-05-29 Esoterix Genetic Laboratories, LLC Identification of differentially represented fetal or maternal genomic regions and uses thereof
EP2633311A4 (en) 2010-10-26 2014-05-07 Univ Stanford Non-invasive fetal genetic screening by sequencing analysis
CN103620055A (en) 2010-12-07 2014-03-05 利兰·斯坦福青年大学托管委员会 Non-invasive determination of fetal inheritance of parental haplotypes at the genome-wide scale
WO2012129363A2 (en) 2011-03-24 2012-09-27 President And Fellows Of Harvard College Single cell nucleic acid detection and analysis
US8688388B2 (en) 2011-10-11 2014-04-01 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
EP2823306A4 (en) 2012-03-09 2015-11-11 Caris Life Sciences Switzerland Holdings Gmbh Biomarker compositions and methods
CA2869371C (en) * 2012-04-06 2021-01-12 The Chinese University Of Hong Kong Noninvasive prenatal diagnosis of fetal trisomy by allelic ratio analysis using targeted massively parallel sequencing
US20150284783A1 (en) 2012-05-21 2015-10-08 Agena Bioscience, Inc. Methods and compositions for analyzing nucleic acid
US20160040229A1 (en) 2013-08-16 2016-02-11 Guardant Health, Inc. Systems and methods to detect rare mutations and copy number variation
KR102393608B1 (en) 2012-09-04 2022-05-03 가던트 헬쓰, 인크. Systems and methods to detect rare mutations and copy number variation
CA2892617C (en) 2012-11-26 2017-01-24 The University Of Toledo Methods for standardized sequencing of nucleic acids and uses thereof
US9944973B2 (en) 2012-11-26 2018-04-17 The University Of Toledo Methods for standardized sequencing of nucleic acids and uses thereof
US10643738B2 (en) * 2013-01-10 2020-05-05 The Chinese University Of Hong Kong Noninvasive prenatal molecular karyotyping from maternal plasma
WO2014127484A1 (en) 2013-02-21 2014-08-28 British Columbia Cancer Agency Branch Spike-in control nucleic acids for sample tracking
JP6633514B2 (en) * 2013-04-25 2020-01-22 ファイアフライ バイオワークス， インコーポレイテッド Multiplex analysis of target nucleic acids
JP5789720B2 (en) 2013-07-31 2015-10-07 株式会社日立製作所 Gene mutation analysis apparatus, gene mutation analysis system, and gene mutation analysis method
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
EP3052632A4 (en) 2013-10-04 2017-03-29 Rana Therapeutics, Inc. Compositions and methods for treating amyotrophic lateral sclerosis
WO2015058086A1 (en) 2013-10-18 2015-04-23 Good Start Genetics, Inc. Methods for copy number determination
CN105829589B (en) 2013-11-07 2021-02-02 小利兰·斯坦福大学理事会 Cell-free nucleic acids for analysis of human microbiome and components thereof
HUE049094T2 (en) 2014-10-01 2020-09-28 Chronix Biomedical Methods of quantifying cell-free dna
CA2965849A1 (en) 2014-12-16 2016-06-23 Garvan Institute Of Medical Research Sequencing controls
FR3031369B1 (en) 2015-01-07 2017-10-20 Valeo Embrayages TORSION OSCILLATION DAMPING DEVICE
US10844428B2 (en) 2015-04-28 2020-11-24 Illumina, Inc. Error suppression in sequenced DNA fragments using redundant reads with unique molecular indices (UMIS)
JP2018525703A (en) * 2015-05-28 2018-09-06 イミューンエクスプレス・プロプライエタリー・リミテッドＩｍｍｕｎｅＸｐｒｅｓｓ Ｐｔｙ Ｌｔｄ Validation of biomarker measurement
MX2018011429A (en) 2016-03-25 2019-06-06 Karius Inc Synthetic nucleic acid spike-ins.
ES2915074T3 (en) 2016-05-31 2022-06-20 Translational Genomics Res Inst Molecular labeling methods and sequencing libraries
EP3497218B1 (en) 2016-08-08 2022-03-16 Karius, Inc. Reduction of signal from contaminant nucleic acids
US11519024B2 (en) * 2017-08-04 2022-12-06 Billiontoone, Inc. Homologous genomic regions for characterization associated with biological targets
US11646100B2 (en) * 2017-08-04 2023-05-09 Billiontoone, Inc. Target-associated molecules for characterization associated with biological targets
US20210292829A1 (en) * 2020-03-23 2021-09-23 Billiontoone, Inc. High throughput assays for detecting infectious diseases using capillary electrophoresis

Also Published As

Publication number Publication date
AU2018312117B2 (en) 2022-05-12
EP3662085B1 (en) 2022-06-22
JP7387110B2 (en) 2023-11-28
KR20200098475A (en) 2020-08-20
JP2022008482A (en) 2022-01-13
JP2020529202A (en) 2020-10-08
US11430543B2 (en) 2022-08-30
US20190095577A1 (en) 2019-03-28
CA3202766A1 (en) 2019-02-07
CN111094583A (en) 2020-05-01
BR112020002260A2 (en) 2020-09-08
WO2019028470A2 (en) 2019-02-07
ES2923478T3 (en) 2022-09-27
EP3662085A4 (en) 2021-05-05
KR102372572B1 (en) 2022-03-08
CA3071366C (en) 2023-08-01
CA3071366A1 (en) 2019-02-07
EP3662085A2 (en) 2020-06-10
IL272399A (en) 2020-03-31
AU2018312117A1 (en) 2020-02-06
JP6955732B2 (en) 2021-10-27
US20230197202A1 (en) 2023-06-22
WO2019028470A3 (en) 2019-06-06

Similar Documents

Publication Publication Date Title
SG11202000444PA (en) Sequencing output determination and analysis with target-associated molecules in quantification associated with biological targets
SG11201909154SA (en) Bispecific antibodies specifically binding to pd1 and lag3
SG11201806190TA (en) Isotachophoresis for purification of nucleic acids
SG11201909205YA (en) Immunoconjugates of an anti-pd-1 antibody with a mutant il-2 or with il-15
SG11201809913PA (en) Methods for detecting target nucleic acids in a sample
SG11201903519UA (en) Methods and systems for barcoding nucleic acid molecules from individual cells or cell populations
SG11201908489XA (en) De novo synthesized combinatorial nucleic acid libraries
SG11201804086VA (en) Methods and compositions for nucleic acid analysis
SG11201808820QA (en) Methods and kits for the diagnosis and risk stratification of patients with ischemia
SG11201804506RA (en) Systems and methods for rendering multiple levels of detail
SG11201908549RA (en) Automated quality control and spectral error correction for sample analysis instruments
SG11201901371XA (en) Methods for the detection of genomic copy changes in dna samples
SG11201907764PA (en) Methods for screening infections
SG11201810611YA (en) Coumarin compounds and their uses as fluorescent labels
SG11201805906WA (en) Diagnostic and prognostic methods for cardiovascular diseases and events
SG11201908767QA (en) Method for accurate diagnosis of a disease targeting biomarkers in liquid biopsy
SG11201908509TA (en) Biosensors for biological or chemical analysis and methods of manufacturing the same
SG11201901730QA (en) Method and system for crispr-based library preparation and sequencing
SG11201906717SA (en) Methods and systems for associating physical and genetic properties of biological particles
SG11201909916YA (en) Compositions and methods for improving sample identification in indexed nucleic acid libraries
SG11201811315PA (en) Reagent channel mixing system and method
SG11201907607VA (en) Use of biomarkers in identifying cancer patients that will be responsive to treatment with a prmt5 inhibitor
SG11201809252YA (en) Methods for determining dpp3 and therapeutic methods
SG11201806432PA (en) Methods for assessing risk of developing colorectal cancer
SG11201907208XA (en) Radiolabeled anti-lag3 antibodies for immuno-pet imaging